NEW YORK (GenomeWeb News) – Gene Bridges said today that the Chugai Pharmaceutical has expanded a license for the company's recombination technology.
The Japanese pharmaceutical firm agreed to expand a commercial license for the Red/ET technology that the companies originally struck in 2005.
Patented in Japan as a "Novel DNA Cloning Method," the Red/ET technology is used for generating targeting vectors or modifying E. coli chromosomes. The methodology allows cloning, subcloning, and DNA modification at any position, Gene Bridges said.
Gene Bridges is a spin-off from the European Molecular Biology Laboratory and is based in Heidelberg, Germany.
Financial terms of the agreement were not released.